Comparative Pharmacology
Head-to-head clinical analysis: EMPRACET W CODEINE PHOSPHATE 4 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPRACET W CODEINE PHOSPHATE 4 versus QDOLO.
EMPRACET W/ CODEINE PHOSPHATE #4 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine by CYP2D6, acting as a mu-opioid receptor agonist. Acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways, reducing pain and fever.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1-2 tablets (acetaminophen 300 mg / codeine phosphate 60 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Acetaminophen: 2-3 hours (prolonged in hepatic insufficiency). Codeine: 2.5-3.5 hours; morphine (active metabolite): 1.5-4.5 hours.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: ~90% as unchanged acetaminophen and metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), 5% unchanged; codeine: ~90% renal as metabolites (codeine-6-glucuronide, norcodeine, morphine, morphine-3-glucuronide, morphine-6-glucuronide), <15% unchanged.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist